WO2005042497A2 - Benzimidazoles convenant comme modulateurs des canaux ioniques - Google Patents

Benzimidazoles convenant comme modulateurs des canaux ioniques Download PDF

Info

Publication number
WO2005042497A2
WO2005042497A2 PCT/US2004/036297 US2004036297W WO2005042497A2 WO 2005042497 A2 WO2005042497 A2 WO 2005042497A2 US 2004036297 W US2004036297 W US 2004036297W WO 2005042497 A2 WO2005042497 A2 WO 2005042497A2
Authority
WO
WIPO (PCT)
Prior art keywords
pain
ring
independently selected
formula
aliphatic
Prior art date
Application number
PCT/US2004/036297
Other languages
English (en)
Other versions
WO2005042497A3 (fr
Inventor
Dean M. Wilson
Andreas P. Termin
Jesus E. Gonzalez Iii
Nicole Zimmermann
Yulian Zhang
Lev T. D. Fanning
Original Assignee
Vertex Pharmaceuticals, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals, Incorporated filed Critical Vertex Pharmaceuticals, Incorporated
Priority to AU2004285053A priority Critical patent/AU2004285053B2/en
Priority to EP04796881A priority patent/EP1678145A2/fr
Priority to US10/977,609 priority patent/US7309716B2/en
Priority to JP2006538402A priority patent/JP2007521325A/ja
Priority to CA002543918A priority patent/CA2543918A1/fr
Priority to NZ547109A priority patent/NZ547109A/en
Publication of WO2005042497A2 publication Critical patent/WO2005042497A2/fr
Publication of WO2005042497A3 publication Critical patent/WO2005042497A3/fr
Priority to IL175252A priority patent/IL175252A0/en
Priority to NO20062426A priority patent/NO20062426L/no
Priority to US11/933,724 priority patent/US7705031B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to compounds useful as inhibitors of voltage-gated sodium channels.
  • the invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.
  • Na channels are central to the generation of action potentials in all excitable cells such as neurons and myocytes. They play key roles in excitable tissue including brain, smooth muscles of the gastrointestinal tract, skeletal muscle, the peripheral nervous system, spinal cord and airway. As such they play key roles in a variety of disease states such as epilepsy (See, Moulard, B. and D. Bertrand (2002) "Epilepsy and sodium channel Mockers” Expert Opin. Ther. Patents 12(1): 85-91)), pain (See, Waxman, S. G., S. Dib-Hajj, et al.
  • Voltage gated Na channels comprise a gene family consisting of 9 different subtypes (NaVl.l-NaV1.9). As shown in Table 1, these subtypes show tissue specific localization and functional differences (See, Goldin, A. L. (2001) "Resurgence of sodium channel research” Annu Rev Physiol 63: 871-94). Three members of the gene family (NaV1.8, 1.9, 1.5) are resistant to block by the well-known Na channel blocker TTX, demonstrating subtype specificity within this gene family. Mutational analysis has identified glutamate 387 as a critical residue for TTX binding (See. Noda, M., H. .Suzuki, et al.
  • NaVs voltage-gated sodium channels
  • Antagonists of NaV channels can attenuate these pain signals and are useful for treating a variety of pain conditions, including but not limited to acute, chronic, inflammatory, and neuropathic pain.
  • Known NaV antagonists such as TTX, lidocaine (See, Mao, J. and L. L. Chen (2000) "Systemic lidocaine for neuropathic pain relief Pain 87(1): 7-17.) bupivacaine, phenytoin (See, Jensen, T. S.
  • TTX-resistant current is insensitive to micromolar concentrations of tetrodotoxin, and displays slow activation and inactivation kinetics and a more depolarized activation threshold when compared to other voltage-gated sodium channels.
  • TTX-resistant sodium currents are primarily restricted to a subpopulation of sensory neurons likely to be involved in nociception. Specifically, TTX-resistant sodium currents are expressed almost exclusively in neurons that have a small cell-body diameter; and give rise to small-diameter slow-conducting axons and that are responsive to capsaicin.
  • a large body of experimental evidence demonstrates that TTX-resistant sodium channels are expressed on C-fibers and are important in the transmission of nociceptive information to the spinal cord.
  • NaV1.8 protein is upregulated along uninjured C-fibers adjacent to the nerve injury. Antisense treatment prevents the redistribution of NaV1.8 along the nerve and reverses neuropathic pain.
  • NaV1.3 is expressed in the central and peripheral systems of man.
  • NaV1.9 is similar to NaV1.8 as it is selectively localized to small sensory neurons of the dorsal root ganglion and trigeminal ganglion (See, Fang, X., L. Djouhri, et al. (2002).
  • the resting membrane potential of NaV1.9 expressing cells is in the -55 to -50mV range compared to -65mV for most other peripheral and central neurons.
  • This persistent depolarization is in large part due to the sustained low-level activation of NaV1.9 channels.
  • This depolarization allows the neurons to more easily reach the threshold for firing action potentials in response to nociceptive stimuli.
  • Compounds that block the NaV1.9 channel may play an important role in establishing the set point for detection of painful stimuli. In chronic pain states, nerve and nerve ending can become swollen and hypersensitive exhibiting high frequency action potential firing with mild or even no stimulation. These pathologic nerve swellings are termed neuromas and the primary Na channels expressed in them are NaV1.8 and NaV1.7 (See, Kretschmer, T., L.
  • NaV1.6 and NaV1.7 are also expressed in dorsal root ganglion neurons and contribute to the small TTX sensitive component seen in these cells. NaV1.7 in particular my therefore be a potential pain target in addition to it's role in neuroendocrine excitability (See, Klugbauer, N., L. Lacinova, et al.
  • NaVl.l See, Sugawara, T., E. Mazaki-Miyazaki, et al. (2001) "Navl.l mutations cause febrile seizures associated with afebrile partial seizures.” Neurology 57(4): 703-5.
  • NaV1.2 See, Sugawara, T., Y. Tsurubuchi, et al.
  • Na channel blockers are currently used or being tested in the clinic to treat epilepsy (.See, Moulard, B. and D. Bertrand (2002) “Epilepsy and sodium channel blockers” Expert Opin. Ther. Patents 12(1): 85-91.); acute (See, Wiffen, P., S. Collins, et al. (2000) “Anticonvulsant drugs for acute and chronic pain” Cochrane Database Svst Rev 3), chronic (See, Wiffen, P., S. Collins, et al. (2000) "Anticonvulsant drugs for acute and chronic pain” Cochrane Database Syst Rev 3, and Guay, D. R.
  • Narasimhan (1997) “Sodium channels and therapy of central nervous system diseases” Adv Pharmacol 39: 47-98) and as anesthetics (See, Strichartz, G. R., Z. Zhou, et al. (2002) "Therapeutic concentrations of local anaesthetics unveil the potential role of sodium channels in neuropathic pain.” Novartis Found Symp 241: 189-201).
  • Chronic headache pain see, Willimas & Stark, Cephalalgia. 2003; 23(10):963-71
  • migraine see, Yamamura, H, et al., J Neurophysiol. 1999; 81(2):479-93
  • tension headache including, cluster headaches (see, Costa, A., et al., Cephalalgia. 2000; 20(2):85-91); chronic neuropathic pain, including, post-herpetic neuralgia (see, Attal, N., et al., Neurology.
  • pelvic pain renal colic pain, acute obstetric pain, including, labor pain (see, Segal, S., et al., Anesth Analg. 1998; 87(4):864- 9); cesarean section pain; acute inflammatory, burn and trauma pain; acute intermittent pain, including, endometriosis (see, Cason, A. M., et al.,Horm Behav. 2003; 44(2):123-31); acute herpes zoster pain; sickle cell anemia; acute pancreatitis (see, Toma, H; Gastroenterology.
  • orofacial pain including, sinusitis pain, dental pain (see, Nusstein, J., et al., J Endod. 1998; 24(7):487-91; Chidiac, J. J., et al., Eur J Pain. 2002 6(l):55-67); multiple sclerosis (MS) pain (see, Sakurai & Kanazawa, J Neurol Sci. 1999 162(2): 162-8); pain in depression (see, Greene B, Curr Med Res Opin.
  • leprosy pain leprosy pain
  • behcet's disease pain adiposis dolorosa
  • phlebitic pain Guillain-Barre pain; painful legs and moving toes; Haglund syndrome; erythromelalgia pain
  • Legroux-Crespel E., et al., Ann Dermatol Venereol. 2003; 130(4):429-33
  • Fabry's disease pain see, Germain, D. P., J Soc Biol.
  • Bladder and urogenital disease including, urinary incontinence (see, Berggren, T., et al, J Urol. 1993; 150(5 Pt 1): 1540-3); hyperactivity bladder (see, Chuang, Y. C, et al., Urology. 2003; 61(3):664-70); painful bladder syndrome (see, Yoshimura, N., et al., J Neurosci. 2001; 21(21):8690-6); interstitial cyctitis (IC) (see, Giannakopoulos& Campilomatos, Arch Ital Urol Nefrol Androl. 1992; 64(4):337-9; Boucher, M., et al., J Urol.
  • Voltage-gated calcium channels are membrane-spanning, multi-subunit proteins that open in response to membrane depolarization, allowing Ca entry from the extracellular milieu.
  • Calcium channels were initially classified based on the time and voltage-dependence of channel opening and on the sensitivity to pharmacological block. The categories were low-voltage activated (primarily T-type) and high-voltage activated (L,N,P,Q or R-type). This classification scheme was replaced by a nomenclature based upon the molecular subunit composition, as summarized in Table I (Hockerman, G. H, et. al. (1997) Annu. Rev. Pharmacol. Toxicol. 37: 361-96; Striessnig, J. (1999) Cell. Physiol. Biochem.
  • Ten isoforms of the 0 subunit are known, as indicated in Table I.
  • the ⁇ ⁇ subunit consists of two disulfide linked subunits, ⁇ 2 , which is primarily extracellular and a transmembrane ⁇ subunit.
  • Four isoforms of ⁇ 2 ⁇ are known, ⁇ 2 ⁇ -l, ⁇ 2 ⁇ -2, ⁇ 2 ⁇ -3 and ⁇ 2 ⁇ -4.
  • the ⁇ subunit is a non-glycosylated cytoplasmic protein that binds to the ⁇ i subunit.
  • Four isoforms are known, termed ⁇ i to ⁇ 4 .
  • the ⁇ subunit is a transmembrane protein that has been biochemically isolated as a component of Ca v l and Ca v 2 channels. At least 8 isoforms are known ( ⁇ ⁇ to ⁇ 8 ) (Kang, M.G. and K. P. Campbell (2003) J. Biol. Chem. 278: 21315-8). The nomenclature for voltage-gated calcium channels is based upon the content of the ⁇ i subunit, as indicated in Table I. Each type of 0 ⁇ subunit can associate with a variety of ⁇ , ⁇ 2 ⁇ or ⁇ subunits, so that each Ca v type corresponds to many different combinations of subunits.
  • Ca v 2 currents are found almost exclusively in the central and peripheral nervous system and in neuroendocrine cells and constitute the predominant orms of presynaptic voltage-gated calcium current. Presynaptic action potentials cause channel opening and neurotransmitter release is steeply dependent upon the subsequent calcium entry. Thus, Ca v 2 channels play a central role in mediating neurotransmitter release.
  • Ca v 2.1 and Ca v 2.2 contain high affinity binding sites for the peptide toxins D-conotoxin- MVIIC and D-conotoxin-GVIA, respectively, and these peptides have been used to determine the distribution and function of each channel type.
  • Ca v 2.2 is highly expressed at the presynaptic nerve terminals of neurons from the dorsal root ganglion and neurons of lamina I and II of the dorsal horn (Westenbroek, R. E., et al. (1998) J. Neurosci. 18: 6319-30; Cizkova, D, et al. (2002) Exp. Brain Res. 147: 456-63).
  • Ca ⁇ 2.2 channels are also found in presynaptic terminals between second and third order interneurons in the spinal cord. Both sites of neurotransmission are very important in relaying pain information to the brain.
  • Acute pain serves an important protective function in keeping the organism safe from stimuli that may produce tissue damage. Severe thermal, mechanical, or chemical inputs have the potential to cause severe damage to the organism if unheeded.
  • Acute pain serves to quickly remove the individual from the damaging environment. Acute pain by its very nature generally is short lasting and intense. Inflammatory pain, on the other hand, may last for much longer periods of time and its intensity is more graded. Inflammation may occur for many reasons including tissue damage, autoimmune response, and pathogen invasion.
  • Inflammatory pain is mediated by a variety of agents that are released during inflammation, including substance P, t ⁇ stamines; acid, prostaglandin, bradykinin, CGRP, cytokines, ATP, and other agents (Julius, D. and A. I. Basbaum (2001) Nature 413 (6852): 203-10).
  • the third class of pain is neuropathic and involves nerve damage arising from nerve injury or viral infection and results in reorganization of neuronal proteins and circuits yielding a pathologic "sensitized" state that can produce chronic pain lasting for years. This type of pain provides no adaptive benefit and is particularly difficult to treat with existing therapies.
  • Pain, particularly neuropathic and intractable pain is a large unmet medical need. Millions of individuals suffer from severe pain that is not well controlled by current therapeutics.
  • the current drugs used to treat pain include NS AIDS, COX-2 inhibitors, opioids, tricyclic antidepressants, and anticonvulsants.
  • Neuropathic pain has been particularly difficult to treat as it does not respond well to opioids until high doses are reached.
  • Gabapentin is currently the most widely used therapeutic for the treatment of neuropathic pain, although it works in only 60% of patients and has modest efficacy. The drug is generally safe, although sedation is an issue at higher doses.
  • the toxin has an 85% success rate for the treatment of pain in humans with a greater potency than morphine.
  • An orally available antagonist of Ca ⁇ 2.2 should have similar efficacy without the need for intrathecal infusion.
  • Ca ⁇ 2.1 and Ca ⁇ 2.3 are also in neurons of nociceptive pathways and antagonists of these channels could be used to treat pain.
  • Antagonists of Cav2.1, Ca ⁇ 2.2 or Ca ⁇ 2.3 should also be useful for treating other pathologies of the central nervous system that apparently involve excessive calcium entry. Cerebral ischaemia and stroke are associated with excessive calcium entry due to depolarization of neurons.
  • the Ca v 2.2 antagonist ziconotide is effective in reducing infarct size in a focal ischemia model using laboratory animals, suggesting that Ca ⁇ 2.2 antagonists could be used for the treatment of stroke.
  • reducing excessive calcium influx into neurons may be useful for the treatment of epilepsy, traumatic brain injury, Alzheimer's disease, multi-infarct dementia and other classes of dementia,. amyotrophic lateral sclerosis, amnesia, or neuronal damage caused by poison r other toxic substances.
  • Ca ⁇ 2.2 also mediates release of neurotransmitters from neurons of the sympathetic nervous system and antagonists could be used to treat cardiovascular diseases such as hypertension, cardiac arrhythmia, angina pectoris, myocardial infarction, and congestive heart failure.
  • r is 0 to 4.
  • Z is O, N or CH
  • Y and W are independently selected from hydrogen, Formula la:
  • T is a bond or a C 1-6 straight or branched aliphatic chain wherein a methylene unit of T is optionally replaced by a C 3-8 cycloaliphatic group
  • U is -CH 2 - or -CH 2 -CH 2 -
  • X is N-C 1-4 alkyl, NH, O, S, S(O), or SO 2
  • each occurrence of R is independently M-R ;
  • M is a bond or is a C 1-6 alkylidene chain wherein up to two non-adjacent methylene units of M are optionally replaced by C(O), CO 2 , C(O)C(O), C(O)NR, OC(O)NR, NRNR, NRNRC(O), NRC(O), NRCO 2 , NRC(O)NR, S(O), SO 2 , NRSO 2 , SO 2 NR, NRSO 2 NR, O, S, or NR, and R x
  • Ring E is C 6-10 aryl, a 5-10 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 3-10 membered heterocyclyl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; and s is 0 to 8; or Formula lb:
  • D is -C 1-6 alkyl- or a bond; and t is 0 to 5; each occurrence of R is independently selected from hydrogen or an optionally substituted C 1-6 aliphatic group; and each occurrence of R A , R B and R D are independently selected from Rl, R ⁇ , R3, R4 ?
  • Ri is oxo, R6 or (C 1- aliphatic) n -J, wherein: n is 0 or 1; J is halo, CN, NO 2 , CF 3 , OCF 3 , OH, SR 6 , S(O)R 6 , SO 2 R 6 , NH 2 , NHR 6 , N(R 6 ) 2 , NR 6 R 8 , C(O)OH, C(O)OR 6 or OR 6 ; or: two Ri on adjacent ring atoms, taken together, form l,2 ⁇ methylenedioxy or 1,2- ethylenedioxy; R ⁇ is C 1-6 aliphatic, optionally substituted with up to two substituents independently selected from Rl, R ⁇ , or R ⁇ ; R3 is C 3-8 cycloaliphatic, C 6-10 aryl, a 5-10 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen,, or sulfur, or a 3-10.
  • R 4 is OR5, OR 6 , OC(O)R 6 , OC(O)R 5 , OC(O)OR 6 , OC(O)OR5, OC(O)N(R) 2 , OC(O)N(R 5 ) 2 , OC(O)N(RR 5 ), SR 6 , SR 5 , S(O)R 6 , S(O)R 5 , SO 2 R 6 , SO 2 R 5 , SO 2 N(R 6 ) 2 , SO 2 N(R 5 ) 2 , SO 2 NR 5 R 6 , SO3R 6 , SO3R 5 , C(O)R5, C(O)OR 5 , C(O)R 6 , C(O)OR 6 , C(O)N(R 6
  • the present invention provides a compound of formula la, as defined generally above, wherein: (a) when Z is N, Y is hydrogen, W is formula la, A is , and V and Q are each a bond, then: (i) when r is 1 and R A is methyl in the C-5 or C-6 position of the benzimidazole ring, then E is not: unsubstitued phenyl; phenyl substituted in the ortho position with methyl, OMe, or OEt; or phenyl substituted in the para position with OMe or methyl; and (ii) when r is 0, then E is not: unsubstituted phenyl; unsubstituted naphthyl; phenyl substituted in the para position with OEt, Br, OH, or OMe; phenyl substituted in the meta position with chloro; or phenyl substituted in the ortho position with methyl;
  • Another embodiment of the present invention provides a method of treating or lessening the severity of a disease, disorder, or condition selected from acute, chronic, neuropathic, or inflammatory pain, including femur cancer pain; non-malignant chronic bone pain; rheumatoid arthritis; osteoarthritis; spinal stenosis; neuropathic low back pain; neuropathic low back pain; myofascial pain syndrome; fibromyalgia; temporomandibular joint pain; chronic visceral pain, including, abdominal; pancreatic; IBS pain; chronic headache pain; migraine; tension headache, including, cluster headaches; chronic neuropathic pain, including, post- herpetic neuralgia; diabetic neuropathy; FflV- associated neuropathy; trigeminal neuralgia; Charcot-Marie Tooth neuropathy; hereditary sensory neuropathies; peripheral nerve injury; painful neuromas; ectopic proximal and distal discharges; radiculopathy; chemotherapy induced neuropathic pain;
  • R , Z, Y, r, and W are as defined above and in classes and subclasses as desribed herein.
  • a preferred aspect of the present embodiment is where the disease, condition, or disorder is acute, chronic, neuropathic, or inflammatory pain.
  • Another embodiment of the present invention provides a method for treating or lessening the severity of a disease, condition or disorder wherein the disease, condition, or disorder is implicated in the activation of voltage-gated sodium channels comprising administering an effective amount of a compound of Formula I:
  • R A , Z, Y, r, and W are as defined above and in classes and subclasses as desribed herein.
  • a preferred aspect of the present embodiment is where the disease, condition, or disorder is acute, chronic, neuropathic, or inflammatory pain, epilepsy or an epilepsy condition, a neurodegenerative disorder, a psychiatric disorder such as anxiety and depression, myotonia, arrythmia, a movement disorder, a neuroendocrine disorder, ataxia, multiple sclerosis, irritable bowel syndrome, or incontinence.
  • a neurodegenerative disorder such as anxiety and depression, myotonia, arrythmia, a movement disorder, a neuroendocrine disorder, ataxia, multiple sclerosis, irritable bowel syndrome, or incontinence.
  • a particularly preferred aspect of the present embodiment is where the disease, condition, or disorder is acute, chronic, neuropathic, or inflammatory pain.
  • Another preferred aspect of the present embodiment is where the method comprises an additional therapeutic agent.
  • Yet another embodiment of the present invention provides a method of inhibiting NaVl.l, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2 activity in: (a) a patient; or (b) a biological sample; which method comprises administering to said patient, or contacting said biological sample with a compound of Formula I:
  • R A , Z, Y, r, and W are as defined above and in classes and subclasses as desribed herein.
  • the present invention provides compounds of Formula I with substituents that are monovalent, such as R A , R B , R c and R D ; or divalent, such as A, B, and D.
  • substituents that are monovalent, such as R A , R B , R c and R D ; or divalent, such as A, B, and D.
  • asymmetric divalent substituent groups such as -C 1-6 alkyl-NH-, and -C 1- alkyl-O-
  • the orientation of a divalent substituent is set by its left/right orientation relative Formula I as taught in the present specification.
  • this orientation convention is not relevant to symmetrical divalent substituents, such as -C(O)-, or -C 1-6 alkyl-.
  • compounds of the invention may optionally be substituted with one or more substituents, such as are illustrated generally above, or as exemplified by particular classes, subclasses, and species of the invention. It will be appreciated that the phrase “optionally substituted” is used interchangeably with the phrase “substituted or unsubstituted.” In general, the term “substituted”, whether preceded by the term “optionally” or not, refers to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent.
  • an optionally substituted group may have a substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
  • Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds.
  • stable refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and preferably their recovery, purification, and use for one or more of the purposes disclosed herein.
  • a stable compound or chemically feasible compound is one that is " not substantially altered when kept at a temperature of 40°C or less, in the absence of moisture or other chemically reactive conditions, for at least a week.
  • aliphatic means a straight- chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as “carbocycle” “cycloaliphatic” or “cycloalkyl”), that has a single point of attachment to the rest of the molecule.
  • aliphatic groups contain 1-20 aliphatic carbon atoms, i.e., C 1-20 alkyl. In some embodiments, aliphatic groups contain 1-10 aliphatic carbon atoms, i.e., C 1-10 alkyl. In other embodiments, aliphatic groups contain 1-8 aliphatic carbon atoms, i.e., C 1-8 alkyl. In still other embodiments, aliphatic groups contain 1-6 aliphatic carbon atoms, i.e.,
  • aliphatic groups contain 1-4 aliphatic carbon atoms, i.e.,
  • cycloaliphatic refers to a monocyclic C 3 -C 8 hydrocarbon or bicyclic C 8 -C 12 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule wherein any individual ring in said bicyclic ring system has 3-7 members.
  • Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as
  • heteroaliphatic heterocycle
  • heterocyclyl heterocycloaliphatic
  • heterocyclic as used herein means non-aromatic, monocyclic, bicyclic, or tricyclic ring systems in which one or more ring members is an independently selected heteroatom.
  • the "heterocycle”, “heterocyclyl”, “heterocycloaliphatic”, or “heterocyclic” group has three to fourteen ring members in which one or more ring members is a heteroatom independently selected from oxygen, sulfur, nitrogen, or phosphorus, and each ring in the system contains 3 to 7 ring members.
  • heteroatom means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), N ⁇ (as in pyrrolidinyl) or NR + (as in N-substituted pyrrolidinyl)).
  • alkoxy refers to an alkyl group, as previously defined, attached to the principal carbon chain through an oxygen (“alkoxy”) or sulfur
  • thioalkyl refers to the alkoxyl group, methoxy, ethyoxy, propoxy, and butoxy, including for propoxy and butoxy, the straight and branched structures, that is /-propoxy and 72-propoxy; and n-butoxy, z ' -butoxy and sec-butoxy.
  • haloalkyl means alkyl, alkenyl or alkoxy, as the case may be, substituted with one or more halogen atoms.
  • halogen means F, Cl, Br, or I.
  • aryl used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl”, refers to monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members.
  • aryl may be used interchangeably with the term “aryl ring”.
  • aryl also refers to heteroaryl ring systems as defined hereinbelow.
  • heteroaryl used alone or as part of a larger moiety as in “heteroaralkyl” or “heteroarylalkoxy”, refers to monocyclic, bicyclic, and tricyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic, at least one ring in the system contains one or more heteroatoms, and wherein each ring in the system contains 3 to 7 ring members.
  • heteroaryl may be used interchangeably with the term “heteroaryl ring” or the term “heteroaromatic”.
  • An aryl (including aralkyl, aralkoxy, aryloxyalkyl and the like) or heteroaryl (including heteroaralkyl and heteroarylalkoxy and the like) group may contain one or more substituents.
  • Optional substituents on the aliphatic group of R° are selected from NH 2 , NH(C 1-4 aliphatic), N(C 1- aliphatic) 2 , halogen, C 1-4 aliphatic, OH, O(C 1- aliphatic), NO 2 , CN, CO 2 H, CO 2 (C 1-4 aliphatic), O(haloC 1- aliphatic), or haloC 1 .
  • aliphatic wherein each of the foregoing C 1-4 aliphatic groups of R° is unsubstituted.
  • An aliphatic or heteroaliphatic group, or a non-aromatic heterocyclic ring may contain one or more substituents.
  • Optional substituents on the aliphatic group of R * are selected from NH 2 , NH(C 1- aliphatic), N(C 1-4 aliphatic) 2 , halogen, C 1- aliphatic, OH, O(C 1-4 aliphatic), NO 2 , CN, CO 2 H, CO 2 (C 1-4 aliphatic), O(halo C 1- aliphatic), or halo(C 1-4 aliphatic), wherein each of the foregoing C 1- aliphatic groups of R is unsubstituted.
  • Optional substituents on' the aliphatic group or the phenyl ring of R + are selected from NH 2 , NH(C 1- aliphatic), N(C 1-4 aliphatic) 2 , halogen, C 1-4 aliphatic, OH, O(C 1-4 aliphatic), NO 2 , CN, CO 2 H, CO 2 (C 1-4 aliphatic), O(halo C 1-4 aliphatic), or halo(C 1- aliphatic), wherein each of the foregoing C 1-4 aliphatic groups of R + is unsubstituted.
  • C 1-2 oalkylidene chain refers to a straight or branched carbon chain of twenty carbon atoms or less that may be fully saturated or have one or more units of unsaturation and has two points of attachment to the rest of the molecule.
  • structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, (Z) and (E) double bond isomers, and (Z) and (E) conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention. For example, for compounds of formula I:
  • structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures except for the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
  • Such compounds are useful, for example, as analytical tools or probes in biological assays.
  • the present invention provides a compound of formula I wherein V is -S(O) 2 -.
  • the present invention provides a compound of formula I wherein V is -C(O)-.
  • T is a C 1-6 straight or branched aliphatic chain wherein a methylene unit of T is optionally replaced by a C 3-6 cycloaliphatic group.
  • Ring E is naphthyl.
  • a compound of formula I wherein Ring E is pyridinyl is also preferred.
  • Ring E is furanyl
  • Ring E is 3,4-dihydro-2H- chromene.
  • the present invention provides a compound of formula I, wherein Ring E is a preferred group as described above and said group is in combination with the remaining variables of formula I as set forth in the classes and subclasses described herein.
  • each R A of formula I when present, is independently R 6 .
  • each R B of formula I, when present, is independently
  • OR 6 N(R 6 ) 2 , NR 6 C(O)R 6 , halo, R 6 , C(O)R 6 , or NO 2 .
  • the A moiety of formula I when present, is -T-NR 6 -, wherein
  • T is a C ⁇ -6 straight or branched aliphatic chain.
  • a moieties include -CH 2 CH 2 N(CH 3 )-,
  • the present invention provides a compound of formula I wherein A is -T-NH- wherein T is -Gi-6 straight or branched aliphatic chain wherein a . methylene unit of T is replaced by a C 3-6 cycloaliphatic group.
  • Such ' cycloaliphatic groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or cyclooctyl groups.
  • the Q moiety of formula I is a C 1- alkylidene chain wherein one methylene unit of Q is replaced by -O-, -NH-, or -S-.
  • Such Q moieties of formula I include
  • Z is O, N or C.
  • Y is hydrogen
  • Ring E is phenyl
  • W is formula la, wherein V is -C(O)-. as shown in Formula Ha:
  • Q moieties of formula Ha include -CH 2 CH 2 O-, -CH 2 O-, -OCH 2 -, -OCH 2 CH 2 -, -CH(CH 3 )O-, -NHCH 2 -,
  • A is -C 1-6 alkyl -NH-.
  • Particularly preferred is a compound of Formula Ila, wherein A is -CH 2 CH 2 NH-.
  • the present invention provides a compound of formula Ila, wherein A is -CH 2 CH 2 NH-, Q is -CH 2 O-, and each R B is independently C 1-6 aliphatic, -CHO, or halogen.
  • the present invention provides a compound of formula lib, wherein A is -CH 2 CH 2 NH-, Q is -CH 2 O-, and each R B is inependently methyl, -CHO, fluoro, or chloro.
  • R B groups include methyl, ethyl, butyl, isopropyl, chloro, fluoro, bromo, N(Me) 2 , CF 3 and -CH 2 phenyl.
  • the present invention provides a compound of formula Ila wherein the benzo ring is substituted at one of, or both of, the C-4- and C-5 positions with tert-butyl, fluoro, or methyl.
  • the present invention provides a compound of formula Ila, wherein A is -CH 2 CH 2 NH- or -CH(CH 3 )NH-, Q is -CH 2 O- and each R B is independently C 1-6 aliphatic, -N(R 6 ) 2 , -C(O)R 6 , or halogen.
  • R B groups include methyl, chloro, bromo, ethyl, N(Me) 2 , -C ⁇ CH and C(O)CH 3 .
  • Yet another embodiment of the present invention relates to a compound of formula Ha, wherein A is -CH 2 CH 2 NH-, Q is -CH 2 O-, -NHCH 2 -, or -CH(CH 3 )O-, and each R B is independently C 1-6 aliphatic, -OR 6 , or halogen.
  • R B groups include methyl, ethyl, -OMe, . chloro, bromo, and fluoro.
  • the present invention provides a compound of formula Ila, wherein A is -CH 2 CH 2 NH- or -CH 2 CH(CH 3 )NH-, Q is -CH 2 O-, -NHCH 2 -, -NH-, -CH(CH 3 )O-, or -C(CH 3 ) 2 O-, and each R B is independently C 1-6 aliphatic, -OR 6 , or halogen.
  • R B groups include methyl, ethyl, -OMe, chloro, bromo, and fluoro.
  • the present invention provides a compound of formula Ila wherein r is 2, each R A is fluoro,and is present at the C-4- and C-5 positions.
  • the present invention provides a compound of formula Ha, wherein A is -CH 2 CH 2 NH-, Q is -CH 2 O-, and each R B is independently C 1-6 aliphatic or halogen.
  • the present invention provides a compound of formula Ila, wherein A is -CH 2 CH 2 NH-, Q is -CH 2 O-, and each R B is inependently methyl, isopropyl, fluoro, bromo, or chloro.
  • the present invention provides a compound of formula Ila, wherein A is -CH 2 CH 2 NH-, Q is -CH 2 O-, and each R B is inependently methyl, fluoro, or chloro.
  • the present invention provides a compound of formula Ila, wherein A is -CH 2 CH 2 NH-, Q is -CH 2 O-, and each R B is inependently methyl, bromo, or chloro.
  • A is wherein U is -CH 2 - or -CH 2 CH 2 -.
  • Y is hydrogen
  • Ring E is phenyl
  • W is Formula lb
  • D is a bond, as shown below as formula lib.
  • R A is methyl, chloro or bromo.
  • Particularly preferred is a compound of Formula lib, wherein R A is methyl.
  • R D is -OH, -N(Et) 2 , -OMe, -NHC(O)CH 3 , fluoro, or chloro.
  • the present invention provides a compound of formula III:
  • each R A of formula III when present, is independently R 6 .
  • each R B of formula III, when present, is independently
  • OR 6 N(R 6 ) 2 , NR 6 C(O)R 6 , halo, R 6 , C(O)R 6 , or NO 2 .
  • the Q moiety of formula III is a C 1- alkylidene chain wherein one methylene unit of Q is replaced by -O-, -NH-, or -S-.
  • Such Q moieties of formula III include -CH 2 CH 2 O-, -CH 2 O-, -OCH 2 -, -OCH 2 CH 2 -, -CH(CH 3 )O-, -NHCH 2 -, -C(CH 3 ) 2 O-, and
  • the A moiety of formula III when present, is -T-NR 6 -, wherein T is a C 1-6 straight or branched aliphatic chain.
  • Such A moieties include
  • the present invention provides a compound of formula III wherein A is -T-NH- wherein T is a C 1-6 straight or branched aliphatic chain wherein a methylene unit of T is replaced by a C 3-6 cycloaliphatic group.
  • cycloaliphatic groups include cyclobutyl, cyclopentyl, and cyclohexyl groups.
  • the present invention provides a compound of formula IV:
  • V, Q, R A , r, R B , n, and s are as defined above and herein.
  • each R A of formula IV when present, is independently R 6 .
  • each R B of formula IV when present, is independently
  • OR 6 N(R 6 ) 2 , NR 6 C(O)R 6 , halo, R 6 , C(O)R 6 , or NO 2 .
  • the Ring E group of formula IV is phenyl or a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or a 3-7 membered monocyclic heterocyclyl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Such Ring E groups of formula IV include pyridyl, thienyl, furyl, and pyrazolyl.
  • the Ring E group of formula IV is an 8-10 membered bicyclic aryl ring or an 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Such Ring E groups of formula IV include naphthyl, quinolinyl, 3,4-dihydro-2H-chromene, and 2,3-dihydrobenzo[b][l,4]dioxine.
  • the Q moiety of formula IV is a C 1-4 alkylidene chain wherein one methylene unit of Q is replaced by -O-, -NH-, or -S-.
  • Such Q moieties of formula IV include -CH 2 CH 2 O-, -CH 2 O-, -OCH 2 -, -OCH 2 CH 2 -, -CH(CH 3 )O-, -NHCH 2 -, -C(CH 3 ) 2 O-, and -CH 2 S-.
  • one of V and Q is a bond.
  • both of V and Q are a bond.
  • the compounds of this invention may be prepared in general by methods known to those skilled in the art for analogous compounds, as illustrated by the general schemes below, and the preparative examples that follow.
  • Starting materials are commercially available from typical chemical reagent supply companies, such as, Aldrich Chemicals Co., Sigma Chemical Company and the like.
  • Compounds that are not commercially available can be prepared by one of ordinary skill in art following procedures set forth in references such as, "Fieser and Fieser's Reagents for Organic Synthesis", Volumes 1-15, John Wiley and Sons, 1991; “Rodd's Chemistry of Carbon Compounds", Volumes 1-5 and Supplementals, Elservier Science Publishers, 1989; and “Organic Reactions", Volumes 1-40, John Wiley and Sons, 1991.
  • Scheme 1 teaches the general preparation of compounds of Formula I. Typically compounds of Formula I, where Y or W is
  • A is -NH-, or -N(C 1-6 alkyl)- are prepared by the coupling of optionally substituted compounds of Formula A, which has a nucleophilic function with optionally substituted compounds of Formula B, which have a terminal electrophilic functionalilty, such as a carboxylic acid, sulfonyl halide, isocyanate, or the like, as defined previously.
  • Scheme 2a teaches the preparation of optionally substituted benzimidazole compounds of Formula II.
  • Scheme 2b teaches the preparation of additional optionally substituted benzimidazole compounds of formula II.
  • Scheme 2b An optionally substituted 1,2-diaminobenzene is reacted with an optionally substituted carboxylic acid with a protected nucleophilic group to provide the benzimidazole intermediate, which is then cyclized to form the benzimidazole moiety.
  • the nucleophilic group is deprotected and acylated, sulfonylated, carbamoylated, or alkylated to provide compounds of Formula II.
  • Scheme 3a teaches the preparation of optionally substituted aryloxy acids.
  • Optionally substituted aryloxy acids are prepared by reacting optionally substituted phenolic compounds with optionally substituted halo-substituted alkyl esters (X is Cl, Br or I) to obtain the corresponding ester.
  • ester compound is then hydrolyzed to obtain a desired optionally substituted compound of Formula B.
  • Protected optionally substituted benzimidazoles of Formula A are prepared by reacting a starting cyano substituted benzimidazole with (Boc) O followed by reduction of the cyano group (Raney-Nickel/H 2 or the like) to provide the desired compound of Formula A.
  • a compound of Formula I, where W is (R D )t is prepared by reacting an optionally substituted di-amino benzene with an optionally substituted benzaldehyde or benzoic acid to obtain the corresponding optionally substituted compound of Formula I, where R A , R D , r and t are as taught for Formula I, in a manner analogous to Schemes 2a and 2b.
  • a method for the treatment or lessening the severity of acute, chronic, neuropathic, or inflammatory pain, arthritis, migrane, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, or incontinence comprising administering an effective amount of a compound, or a pharmaceutically acceptable composition comprising a compound to a subject in need thereof.
  • a method for the treatment or lessening the severity of acute, chronic, neuropathic, or inflammatory pain comprising administering an effective amount of a compound or a pharmaceutically acceptable composition to a subject in need thereof.
  • an "effective amount" of the compound or pharmaceutically acceptable composition is that amount effective for treating or lessening the severity of one or more of acute, chronic, neuropathic, or inflammatory pain, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, or incontinence.
  • the compounds of the invention are useful as inhibitors of voltage-gated sodium ion channels or calcium channels, preferably N-type calcium channels.
  • the compounds and compositions of the invention are inhibitors of one or more of NaVl.l, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaVl.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2, and thus, without wishing to be bound by any particular theory, the compounds and compositions are particularly useful for treating or lessening the severity of a disease, condition, or disorder where activation or hyperactivity of one or more of NaVl.l, NaV1.2, NaV1.3, NaVl.4, NaV1.5, NaVl.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2 is implicated in the disease, condition, or disorder.
  • NaVl.l, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2 When activation or hyperactivity of NaVl.l, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2, is implicated in a particular disease, condition, or disorder, the disease, condition, or disorder may also be referred to as a "NaVl.l, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaVl.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2-mediated disease, condition or disorder" or a "CaV2.2-mediated condition or disorder”.
  • the present invention provides a method for treating or lessening the severity of a disease, condition, or disorder where activation or hyperactivity of one or more of NaVl.l, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaVl.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2 is implicated in the disease state.
  • compounds of the invention are useful as inhibitors of NaV1.8.
  • compounds of the invention are useful as inhibitors of NaV1.8 and ' CaV2.2.
  • compounds of the invention are useful as inhibitors of CaV2.2.
  • a pharmaceutically acceptable derivative includes, but is not limited to, pharmaceutically acceptable salts, esters, salts of such esters, or any other adduct or derivative which upon administration to a patient in need is capable of providing, directly or indirectly, a compound as otherwise described herein, or a metabolite or residue thereof.
  • the term “pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgement, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • a “pharmaceutically acceptable salt” means any non-toxic salt or salt of an ester of a compound of this invention that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention or an inhibitorily active metabolite or residue thereof.
  • the term “inhibitorily active metabolite or residue thereof” means that a metabolite or residue thereof is also an inhibitor of a voltage-gated sodium ion channel.
  • compositions of this invention include those derived from suitable inorganic and organic acids and bases.
  • Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
  • organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lautyl sulfate, malate, maleate, rnalbnate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, peroxine sodium
  • Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and N + (C 1- alkyl) 4 salts.
  • This invention also envisions the quaternization of any basic nitrogen-containing groups of the compounds disclosed herein. Water or oil-soluble or dispersable products may be obtained by such quaternization.
  • Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
  • compositions are provided.
  • the pharmaceutically acceptable compositions of the present invention additionally comprise a pharmaceutically acceptable carrier, adjuvant, or vehicle, which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • a pharmaceutically acceptable carrier, adjuvant, or vehicle which, as used herein, includes any and all solvents, diluents, or other liquid vehicle, dispersion or suspension aids, surface active agents, isotonic agents, thickening or emulsifying agents, preservatives, solid binders, lubricants and the like, as suited to the particular dosage form desired.
  • Remington's Pharmaceutical Sciences, Sixteenth Edition, E. W. Martin (Mack Publishing Co., Easton, Pa., 1980) discloses various carriers used in formulating pharmaceutically acceptable compositions
  • any conventional carrier medium is incompatible with the compounds of the invention, such as by producing any undesirable biological effect or otherwise interacting in a deleterious manner with any other component(s) of the pharmaceutically acceptable composition, its use is contemplated to be within the scope of this invention.
  • materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, or potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, " polyvinyl pyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, wool fat, sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; tal
  • a method for the treatment or lessening the severity of acute, chronic, neuropathic, or inflammatory pain, arthritis, migrane, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, or incontinence comprising administering an effective amount of a compound, or a pharmaceutically acceptable composition comprising a compound to a subject in need thereof.
  • a method for the treatment or lessening the severity of acute, chronic, neuropathic, or inflammatory pain comprising administering an effective amount of a compound or a pharmaceutically acceptable composition to a subject in need thereof.
  • an "effective amount" of the compound or pharmaceutically acceptable composition is that amount effective for treating or lessening the severity of one or more of acute, chronic, neuropathic, or inflammatory pain, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, or incontinence.
  • the compounds and compositions, according to the method of the present invention may be administered using any amount and any route of administration effective for treating or lessening the severity of one or more of acute, chronic, neuropathic, or inflammatory pain, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, myotonia, arrythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, or incontinence.
  • the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the infection, the particular agent, its mode of administration, and the like.
  • the compounds of the invention are preferably formulated in dosage unit form for ease of administration and uniformity of dosage.
  • dosage unit form refers to a physically discrete unit of agent appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the specific effective dose level for any particular patient or organism will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed, and like factors well known in the medical arts.
  • patient means an animal, preferably a mammal, and most preferably a human.
  • compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated.
  • the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.
  • Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs.
  • the liquid dosage forms may contain inert diluents, commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents commonly used in the art such as, for example, water or other solvents
  • the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • injectable preparations for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.
  • injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
  • a compound of the present invention In order to prolong the effect of a compound of the present invention, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound m biodegradable polymers such as polylactide- polyglycolide.
  • the rate of compound release can be controlled.
  • biodegradable polymers include poly(orthoesters) and poly(anhydrides).
  • Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.
  • compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar— agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl
  • Solid compositions of a similar type may also be employed as fillers in soft and hard- filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifymg agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.
  • the active compounds can also be in microencapsulated form with one or more excipients as noted above.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical formulating art.
  • the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch.
  • Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose.
  • the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
  • Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches.
  • the active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required.
  • Ophthalmic formulation, eardrops, and eye drops are also contemplated as being within the scope of this invention. Additionally, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms are prepared by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
  • the compounds of the invention are useful as inhibitors of voltage-gated sodium ion channels.
  • the compounds and compositions of the invention are inhibitors of one or more of NaVl.l, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaVl.6, NaV1.7, NaVl.8, NaV1.9, or CaV2.2 and thus, without wishing to be bound by any particular theory, the compounds and compositions are particularly useful for treating or lessening the severity of a disease, condition, or disorder where activation or hyperactivity of one or-more of NaVl.l, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaVl.6, NaVL7, NaV1.8, NaV1.9, or CaV2.2 is implicated in the disease, condition, or disorder, When activation or hyperactivity of NaVl.l, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2 is implicated in
  • the present invention provides a method for treating or lessening the severity of a disease, condition, or disorder where activation or hyperactivity of one or more of NaVl.l, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaVl.6, NaV1.7, NaV1.8 or NaV1.9 is implicated in the disease state.
  • the activity of a compound utilized in this invention as an inhibitor of NaVl.l, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2 may be assayed according to methods described generally in the Examples herein.
  • the compounds and pharmaceutically acceptable compositions of the present invention can be employed in combination therapies, that is, the compounds and pharmaceutically acceptable compositions can be administered concurrently with, prior to, or subsequent to, one or more other desired therapeutics or medical procedures.
  • the particular combination of therapies (therapeutics or procedures) to employ in a combination regimen will take into account compatibility of the desired therapeutics and/or procedures and the desired therapeutic effect to be achieved.
  • the therapies employed may achieve a desired effect for the same disorder (for example, an inventive compound may be administered concurrently with another agent used to treat the same disorder), or they may achieve different effects (e.g., control of any adverse effects).
  • additional therapeutic agents that are normally administered to treat or prevent a particular disease, or condition, are known as "appropriate for the disease, or condition, being treated".
  • the amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent.
  • the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.
  • the present invention in another aspect, includes a composition for coating an implantable device comprising a compound of the present invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device.
  • the present invention includes an implantable device coated with a composition comprising a compound of the present invention as described generally above, and in classes and subclasses herein, and a carrier suitable for coating said implantable device.
  • Suitable coatings and the general preparation of coated implantable devices are described in US Patents 6,099,562; 5,886,026; and 5,304,121.
  • the coatings are typically biocompatible polymeric materials such as a hydrogel polymer, polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof.
  • the coatings may optionally be further covered by a suitable topcoat of fluorosilicone, polysaccarides, polyethylene glycol, phospholipids or combinations thereof to impart controlled release characteristics in the composition.
  • Another aspect of the invention relates to inhibiting NaVl.l, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaVl.8, NaV1.9, or CaV2.2 activity in a biological sample or a patient, which method comprises administering to the patient, or contacting said biological sample with a compound of formula I or a composition comprising said compound.
  • biological sample includes, without limitation, cell cultures or extracts thereof; biopsied material obtained from a mammal or extracts thereof; and blood, saliva, urine, feces, semen, tears, or other body fluids or extracts thereof.
  • Inhibition of NaVl.l, NaV1.2, NaV1.3, NaV1.4, NaV1.5, NaV1.6, NaV1.7, NaV1.8, NaV1.9, or CaV2.2 activity in a biological sample is useful for a variety of purposes that are known to one of skill in the art. Examples of such purposes include, but are not limited to, the study of sodium ion channels in biological and pathological phenomena; and the comparative evaluation of new sodium ion channel inhibitors.
  • Boc-protected benzimidazole ethyl amme 3 (400 mg, 1.53 mmol) was dissolved m THF (50 mL) and cooled to 0°C under nitrogen, followed by dropwise addition of LiHMDS (535 mg, 3.37 mmol) in THF(10 mL) via syringe. The mixture was warmed to room temperature and stirred for 20 min. Methyl iodide (0.1 mL, 1.68 mmol) was .added dropwise to the reaction mixture. After stirring for 5 h at room temperature, the reaction was quenched with water (20 mL) and extracted with EtOAc (30 mL x 2), dried, concentrated and purified by IS CO flash chromatography.
  • This example teaches the preparation of [2-(lH-benzoimidazol-2-yl)-ethyl]-carbamic acid 3,4- dimethyl-benzyl ester.
  • This example teaches the preparation of 2-(2,6-Difluoro-phenyl)-7-methyl-lH-benzoimidazole according to the following procedure.
  • a solution of 3-methyl-benzene-l,2-diamine (100 mg, 0.82 mmol) and 2,6-difluorobenzaldehyde in EtO ⁇ (2 mL) was heated for 5 min at 180°C in a microwave synthesizer.
  • the EtO ⁇ was removed, the residue was dissolved in DMSO (1 mL), and was purified on a Gilson ⁇ PLC to afford 2-(2,6-difluoro-phenyl)-7-methyl-lH- benzoimidazole as TFA salt (200 mg) at 100% yield.
  • Micromass MUX LCT 4 channel LC/MS Waters 60F pump, Gilson 215 4 probe autosampler, Gilson 849 injection module, 1.5 mL/min/column flow rate, 10-99% CH 3 CN (0.035 % TFA) / H 2 O (0.05 % TFA) gradient, Phenomenex Luna 5u C18 columns (50 x 4.60 mm), Waters MUX UV-2488 UV detector, Cedex 75 ELSD detectors.
  • A) Optical methods for assaying NaV inhibition properties of compounds [00151] Compounds of the invention are useful as antagonists of voltage-gated sodium ion channels. Antagonist properties of test compounds were assessed as follows. Cells expressing the NaV of interest were placed into microtiter plates. After an incubation period, the cells were stained with fluorescent dyes sensitive to the transmembrane potential. The test compounds were added to the microtiter plate. The cells were stimulated with either a chemical or electrical means to evoke a NaV dependent membrane potential change from unblocked channels, which was detected and measured with trans-membrane potential-sensitive dyes. Antagonists were detected as a decreased membrane potential response to the stimulus.
  • the optical membrane potential assay utilized voltage-sensitive FRET sensors described by Gonzalez and Tsien (See, Gonzalez, J. E. and R. Y. Tsien (1995) "Voltage sensing by fluorescence resonance energy transfer in single cells” Biophys J 69(4): 1272-80, and Gonzalez, J. E. and R. Y. Tsien (1997) "Improved indicators of cell membrane potential that use fluorescence resonance energy transfer” Chem Biol 4(4): 269-77) in combination with instrumentation for measuring fluorescence changes such as the Voltage/Ion Probe Reader (VD?R ® ) (See, Gonzalez, J. E., K. Oades, et al. (1999) "Cell-based assays and instrumentation for screening ion-channel targets” Drug Discov Today 4(9): 431-439).
  • VD?R ® Voltage/Ion Probe Reader
  • CHO cells endogenously expressing a NaV1.2 type voltage-gated NaV are seeded in 96-well poly-lysine coated plates at 60,000 cells per well.
  • Other subtypes are performed in an analogous mode in a cell line expressing the NaV of interest.
  • a 15 uM CC2-DMPE solution is prepared by mixing 5 mM coumarin stock solution with 10% Pluronic 127 1:1 and then dissolving the mix in the appropriate volume of BS#2.
  • the cells are loaded with 80 ⁇ L of the CC2-DMPE solution. Plates are incubated in the dark for 30 minutes at room temperature.
  • a 15 ⁇ L oxonol solution in BS#2 is prepared.
  • this solution should contain 0.75 mM ABSC1 and 30 ⁇ L veratridine (prepared from 10 mM EtOH stock, Sigma #V-5754). 5) After 30 minutes, CC2-DMPE is removed and the cells are washed twice with 225 ⁇ L of BS#2. As before, the residual volume should be 40 ⁇ L.
  • the cells are loaded with 80 ⁇ L of the DiSBAC 2 (3) solution, after which test compound, dissolved in DMSO, is added to achieve the desired test concentration to each well from the drug addition plate and mixed thoroughly.
  • the volume in the well should be roughly 121 ⁇ L.
  • the cells are then incubated for 20-30 minutes.
  • the data is further reduced by calculating the initial (R,) and final (R f ) ratios. These are the average ratio values during part or all of the pre-stimulation period, and during sample points during the stimulation period.
  • the response to the stimulus R R f /R, is then calculated.
  • baseline 2-7 sec and final response is sampled at 15-24 sec.
  • Control responses are obtained by performing assays in the presence of a compound with the desired properties (positive control), such as tetracaine, and in the absence of pharmacological agents (negative control). Responses to the negative (N) and positive (P) controls are calculated as above.
  • the compound antagonist activity A is defined as: . R - P ' ⁇ 100 . where R is the ratio response of the test compound N - P
  • Bath Solution #1 ⁇ aCl 160, KC1 4.5, CaCl 2 2, MgCl 2 1, HEPES 10, pH 7.4 with ⁇ aOH
  • DiSBAC 2 (3) prepared as a 12 mM stock in DMSO and stored at -20°C ABSC1: prepared as a 200 mM stock in distilled H 2 O and stored at room temperature
  • CHO cells are grown in DMEM (Dulbecco's Modified Eagle Medium; GibcoBRL
  • FBS Fetal Bovine Serum, qualified; GibcoBRL #16140-
  • Pen-Strep Penicillin-Streptomycin; GibcoBRL #15140-122.
  • Cells are grown in vented cap flasks, in 90% humidity and 10% CO 2 , to 100% confluence. They are usually split by trypsinization 1:10 or 1:20, depending on scheduling needs, and grown for 2-3 days before the next split.
  • HEK293 cells stably expressing NaV1.3 are plated into 96-well microtiter plates.
  • the cells are stained with the voltage sensitive dyes CC2-
  • 2X CC2-DMPE 20 ⁇ M CC2-DMPE: 10 mM CC2-DMPE is vortexed with an equivalent volume of 10% pluronic, followed by vortexing in required amount of HBSS containing 10 mM HEPES. Each cell plate will require 5 mL of 2X CC2-DMPE. 50 ⁇ L of 2X
  • CC2-DMPE is to wells containing washed cells, resulting in a 10 ⁇ M final staining concentration. The cells are stained for 30 minutes in the dark at RT.
  • the 2X DiSBAC 2 (3) solution can be used to solvate compound plates. Note that compound plates are made at 2X ' drug concentration. Wash stained plate again, leaving residual ' volume of 50 ⁇ L. Add 50 uL/well of the 2X DiSBAC 2 (3) w/ ABSC1. Stain for 30 minutes in the dark at RT.
  • the instrument comprises a microtiter plate handler, an optical system for exciting the coumarin dye while simultaneously recording the coumarin and oxonol emissions, a waveform generator, a current- or voltage-controlled amplifier, and a device for inserting electrodes in well. Under integrated computer control, this instrument passes user-programmed electrical stimulus protocols to cells within the wells of the microtiter plate.
  • Assay Protocol 1 Insert or use electrodes into each well to be assayed. 2. Use the current-controlled amplifier to deliver stimulation wave pulses for 3 s. Two seconds of pre-stimulus recording are performed to obtain the un-stimulated intensities. Five seconds of post-stimulation recording are performed to examine the relaxation to the resting state.
  • the data is further reduced by calculating the initial (R,) and final (R f ) ratios. These are the average ratio values during part or all of the pre-stimulation period, and during sample points during the stimulation period.
  • the response to the stimulus R R R; is then calculated.
  • Control responses are obtained by performing assays in the presence of a compound with the desired properties (positive control), such as tetracaine, and in the absence of pharmacological agents (negative control). Responses to the negative (N) and positive (P) controls are calculated as above.
  • the compound antagonist activity A is defined as: R - P
  • the "voltage clamp” mode has been used to assess the compound's IC50 holding the cells at - 60 mV.
  • the "current clamp” mode has been employed to test the efficacy of the compounds in blocking action potential generation in response to current injections. The results of these experiments have contributed to the definition of the efficacy profile of the compounds.
  • TTX-resistant sodium currents were recorded from DRG somata using the whole-cell variation of the patch clamp technique. Recordings were made at room temperature (-22° C) with thick walled borosilicate glass electrodes (WPI; resistance 3-4 M ⁇ ) using an Axopatch 200B amplifier (Axon Instruments). After establishing the whole-cell configuration, approximately 15 minutes were allowed for the pipette solution to equilibrate within the cell before beginning recording. Currents were lowpass filtered between 2-5 kHz and digitally sampled at 10 kHz. Series resistance was compensated 60-70% and was monitored continuously throughout the experiment. The liquid junction potential (-7 mV) between the intracellular pipette solution and the external recording solution was not accounted for in the data analysis. Test solutions were applied to the cells with a gravity driven fast perfusion system (SF-77;
  • Intracellular solution in mM: Cs-F (130), NaCl (10), MgCl 2 (1), EGTA (1.5),
  • CURRENT-CLAMP assay for NaV channel inhibition activity of compounds [00177] Cells were current-clamped in whole-cell configuration with a Multiplamp 700A amplifier (Axon Inst). Borosilicate pipettes (4-5 MOhm) were filled with (in mM):150 K- gluconate, 10 NaCl, 0.1 EGTA, 10 Hepes, 2 MgCl 2 , (buffered to pH 7.34 with KOH). Cells were bathed in (in mM): 140 NaCl, 3 KC1, 1 MgCl , 1 CaCl , and 10 Hepes). Pipette potential was zeroed before seal formation; liquid junction potentials were not corrected during acquisition. Recordings were made at room temperature.
  • A) Optical methods for assaying CaV inhibition properties of compounds [00179] Compounds of the invention are useful as antagonists of voltage-gated calcium ion channels. Antagonist properties of test compounds were assessed as follows. Cells expressing the CaV of interest were placed into microtiter plates. After an incubation period, the cells were stained with fluorescent dyes sensitive to the transmembrane potential. The test compounds were added to the microtiter plate. The cells were stimulated with electrical means to evoke a CaV dependent membrane potential change from unblocked channels, which was detected and measured with trans-membrane potential-sensitive dyes. Antagonists were detected as a decreased membrane potential response to the stimulus.
  • the optical membrane potential assay utilized voltage-sensitive FRET sensors described by Gonzalez and Tsien (See, Gonzalez, J. E. and R. Y. Tsien (1995) "Voltage sensing by fluorescence resonance energy transfer in single cells” Biophys J 69(4): 1272-80, and Gonzalez, J. E. and R. Y. Tsien (1997) “Improved indicators of cell membrane potential that use fluorescence resonance energy transfer” Chem Biol 4(4): 269-77) in combination with instrumentation for measuring fluorescence changes such as the Voltage/Ion Probe Reader (VIPR ® ) (See, Gonzalez, J. E., K. Oades, et al. (1999) "Cell- based assays and instrumentation for screening ion-channel targets” Drug Discov Today 4(9): 431-439).
  • VIPR ® Voltage/Ion Probe Reader
  • VIPR ® optical membrane potential assay method with electrical stimulation [00181] The following is an example of how CaV2.2 inhibition activity is measured using the optical membrane potential method. Other subtypes are performed in an analogous mode in a cell line expressing the CaV of interest.
  • HEK293 cells stably expressing CaV2.2 are plated into 96-well microtiter plates. After an appropriate incubation period, the cells are stained with the voltage sensitive dyes CC2- DMPE/DiSBAC2(3) as follows.
  • Pluronic F-127 100 mg/mL Pluronic F-127 (Sigma #P2443), in dry DMSO 10 mM DiSBAC 6 (3) (Aurora #00-100-010) in dry DMSO 10 mM CC2-DMPE (Aurora #00-100-008) in dry DMSO
  • 2X CC2-DMPE 20 ⁇ M CC2-DMPE: 10 mM CC2-DMPE is vortexed with an equivalent volume of 10% pluronic, followed by vortexing in required amount of HBSS containing 10 mM HEPES. Each cell plate will require 5 mL of 2X CC2-DMPE. 50 ⁇ L of 2X
  • CC2-DMPE is added to wells containing washed cells, resulting in a 10 ⁇ M final staining concentration. The cells are stained for 30 minutes in the dark at RT.
  • 5X AY17 750 ⁇ M AY17 with 15mM BaCl 2 : Add Acid Yellow 17 to vessel containing Bath X. Mix well. Allow solution to sit for 10 minutes. Slowly mix in 370mM
  • BaCl 2 This solution can be used to solvate compound plates. Note that compound plates are made at 1.5X drug concentration and not the usual 2X. Wash CC2 stained plate, again, leaving residual volume of 50 ⁇ L. Add 100 uIJwell of the AY17 solution. Stain forl5 minutes in the dark at RT. Run plate on the optical reader.
  • the instrument comprises a microtiter, plate handler, an optical system for exciting the coumarin dye while simultaneously recording the coumarin and oxonol emissions, a waveform generator, a current- or voltage-controlled amplifier, and a device for inserting electrodes in well. Under integrated computer control, this instrument passes user-programmed electrical stimulus protocols to cells within the wells of the microtiter plate.
  • the data is further reduced by calculating the initial (R,) and final (R f ) ratios. These are the average ratio values during part or all of the pre-stimulation period, and during sample points during the stimulation period.
  • the response to the stimulus R R f /Ri is then calculated.
  • Control responses are obtained by performing assays in the presence of a compound with the desired properties (positive control), such as mibefradil, and in the absence of pharmacological agents (negative control). Responses to the negative (N) and positive (P) controls are calculated as above.
  • the compound antagonist activity A is defined as: D
  • VOLTAGE-CLAMP assay in HEK293 cells expressing CaV2.2 [00194] CaV2.2 calcium currents were recorded from HEK293 cells using the whole-cell variation of the patch clamp technique. Recordings were made at room temperature (-22° C) with thick walled borosilicate glass electrodes (WPI; resistance 3-4 M ⁇ ) using an Axopatch 200B amplifier (Axon Instruments). After establishing the whole-cell configuration, approximately 15 minutes were allowed for the pipette solution to equilibrate within the cell before beginning recording. Currents were lowpass filtered between 2-5 kHz and digitally sampled at 10 kHz. Series resistance was compensated 60-70% and was monitored continuously throughout the experiment. The liquid junction potential (-7 mV) between the intracellular pipette solution and the external recording solution was not accounted for in the data analysis. Test solutions were applied to the cells with a gravity driven fast perfusion system (SF-77; Warner Instruments).
  • SF-77 gravity driven fast perfusion system
  • Extracellular solution (in mM): NaCl (138), BaCl 2 (10), KC1 (5.33), KH PO (0.44),

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Pain & Pain Management (AREA)
  • Structural Engineering (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Materials Engineering (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)

Abstract

La présente invention concerne des composés représentés par la formule (I), ou certains de ses sels pharmaceutiquement admis. Dans cette formule, les groupes R1, Z, Y, RA et W sont tels que définis dans les spécifications. L'invention concerne également des compositions pharmaceutiquement admises, et des procédés permettant d'utiliser ces compositions pour le traitement de divers troubles.
PCT/US2004/036297 2003-10-28 2004-10-28 Benzimidazoles convenant comme modulateurs des canaux ioniques WO2005042497A2 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AU2004285053A AU2004285053B2 (en) 2003-10-28 2004-10-28 Benzimidazoles useful as modulators of ion channels
EP04796881A EP1678145A2 (fr) 2003-10-28 2004-10-28 Benzimidazoles convenant comme modulateurs des canaux ioniques
US10/977,609 US7309716B2 (en) 2003-10-28 2004-10-28 Benzimidazoles useful as modulators of ion channels
JP2006538402A JP2007521325A (ja) 2003-10-28 2004-10-28 イオンチャネルのモジュレーターとして有用なベンズイミダゾール
CA002543918A CA2543918A1 (fr) 2003-10-28 2004-10-28 Benzimidazoles convenant comme modulateurs des canaux ioniques
NZ547109A NZ547109A (en) 2003-10-28 2004-10-28 Benzimidazoles useful as modulators of ion channels
IL175252A IL175252A0 (en) 2003-10-28 2006-04-27 Benzimidazole derivatives and pharmaceutical compositions containing the same
NO20062426A NO20062426L (no) 2003-10-28 2006-05-29 Benzimidazoler nyttige som modulatorer av ionekanaler
US11/933,724 US7705031B2 (en) 2003-10-28 2007-11-01 Benzimidazoles useful as modulators of ion channels

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51508803P 2003-10-28 2003-10-28
US60/515,088 2003-10-28

Publications (2)

Publication Number Publication Date
WO2005042497A2 true WO2005042497A2 (fr) 2005-05-12
WO2005042497A3 WO2005042497A3 (fr) 2005-07-21

Family

ID=34549374

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/036297 WO2005042497A2 (fr) 2003-10-28 2004-10-28 Benzimidazoles convenant comme modulateurs des canaux ioniques

Country Status (13)

Country Link
US (2) US7309716B2 (fr)
EP (1) EP1678145A2 (fr)
JP (1) JP2007521325A (fr)
KR (1) KR20060115396A (fr)
CN (1) CN1902181A (fr)
AU (1) AU2004285053B2 (fr)
CA (1) CA2543918A1 (fr)
IL (1) IL175252A0 (fr)
NO (1) NO20062426L (fr)
NZ (1) NZ547109A (fr)
RU (1) RU2006118312A (fr)
WO (1) WO2005042497A2 (fr)
ZA (1) ZA200603864B (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007007069A1 (fr) * 2005-07-07 2007-01-18 Vernalis (R & D) Limited Composés azacycliques en tant qu’inhibteurs de canaux sodiques spécifiques aux neurones sensoriels
WO2007110221A1 (fr) * 2006-03-27 2007-10-04 Wex Pharmaceuticals Inc. Utilisation d'inhibiteurs des canaux sodiques pour traiter la douleur neuropathique consécutive à une chimiothérapie
EP1904443A1 (fr) * 2005-07-12 2008-04-02 Bayer Cropscience Sa Nouveaux derives benzoheterocyclylethylbenzamide derivatives
JP2009504758A (ja) * 2005-08-15 2009-02-05 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｔｐｏ模倣剤としての化合物および組成物
WO2009049180A2 (fr) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Amides d'hétéroaryle utilisés comme inhibiteurs de canaux sodiques sensibles à une différence de potentiel
JP2009535414A (ja) * 2006-05-03 2009-10-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｖｒ１のベンゾイミダゾール系モジュレーター
US8431597B2 (en) 2007-06-29 2013-04-30 Pfizer Inc. Benzimidazole derivatives
RU2518073C2 (ru) * 2008-12-26 2014-06-10 ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД. Новое бициклическое гетероциклическое соединение
US8946264B2 (en) 2009-03-05 2015-02-03 Daiichi Sankyo Company, Limited Pyridine derivative
EP2681200A4 (fr) * 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd Inhibiteurs de type benzimidazole du canal sodique
WO2018235926A1 (fr) 2017-06-23 2018-12-27 協和発酵キリン株式会社 COMPOSÉ AMIDE α, β-INSATURÉ
KR101938982B1 (ko) 2017-07-17 2019-01-15 연세대학교 산학협력단 자가포식 조절제를 포함하는 대사성 질환 치료용 약학 조성물
KR20190042940A (ko) * 2017-10-17 2019-04-25 성균관대학교산학협력단 Bietpc를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
JP2019131618A (ja) * 2007-11-06 2019-08-08 バイオエレクトロン テクノロジー コーポレイション ミトコンドリア病を治療するための４−（ｐ−キノリル）−２−ヒドロキシブタンアミド誘導体
EP3927330A4 (fr) * 2019-02-19 2022-11-30 The Regents of the University of California Modulateurs du récepteur nurr1
US11897871B1 (en) 2021-06-14 2024-02-13 Scorpion Therapeutics, Inc. Methods for treating cancer

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1330444B1 (fr) 2000-11-01 2011-03-23 Millennium Pharmaceuticals, Inc. Composes heterocycliques azotes et leur procede de fabrication
FR2880889B1 (fr) * 2005-01-14 2007-04-06 Merck Sante Soc Par Actions Si Derives de l'acide 1h-indole-3-carboxylique, procedes pour leur preparation, compositions pharmaceutiques les contenant et applications en therapeutique
AR057455A1 (es) * 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
US9212139B2 (en) 2010-06-16 2015-12-15 Purdue Pharma, L.P. Aryl substituted indoles and their use as blockers of sodium channels
RU2443690C1 (ru) * 2010-12-13 2012-02-27 Российская Федерация, От Имени Которой Выступает Министерство Образования И Науки Российской Федерации 2-(9-антрилметил)амино-1-[3-(диметиламино)пропил]бензимидазол, обладающий свойствами флуоресцентного хемосенсора на катионы h+
EP2758376A4 (fr) 2011-09-19 2015-04-29 Vitas Pharma Res Private Ltd Composés hétérocycliques en tant qu'inhibiteurs de la biosynthèse d'acide gras pour des infections bactériennes
WO2013101911A2 (fr) 2011-12-28 2013-07-04 Allergan, Inc. Dérivés de benzimidazole comme bloqueurs sélectifs de courant sodique persistant
WO2013101926A1 (fr) 2011-12-28 2013-07-04 Allergan, Inc. Dérivés benzimidazole en tant que bloqueurs sélectifs du courant de sodium persistant
US9828348B2 (en) * 2013-11-08 2017-11-28 Purdue Pharma L.P. Benzimidazole derivatives and use thereof
US20150203812A1 (en) * 2014-01-20 2015-07-23 Francesco Tombola Inhibitors of Voltage Gated Ion Channels
US10913736B2 (en) * 2014-08-22 2021-02-09 University Of Washington Specific inhibitors of methionyl-tRNA synthetase
CN104974103A (zh) * 2015-07-14 2015-10-14 佛山市赛维斯医药科技有限公司 一类含苯并异恶唑和烷氧苯基类结构的化合物及其用途
CN104926745A (zh) * 2015-07-14 2015-09-23 佛山市赛维斯医药科技有限公司 含苯并异恶唑和末端卤代苄基类结构的化合物及其用途
CN108135897B (zh) * 2015-08-20 2021-07-27 勃林格殷格翰国际有限公司 稠合的苯甲酰胺
CN107922350B (zh) * 2015-09-11 2022-04-19 大日本住友制药株式会社 新的苯并咪唑化合物及其医药用途
GB201619694D0 (en) * 2016-11-22 2017-01-04 Entpr Therapeutics Ltd Compounds
MA53521B1 (fr) * 2021-05-12 2023-03-31 Univ Ibn Tofail Nouveaux composés inhibiteurs de la protéase mpro et de la réplication du sars-cov2, leurs formulations et applications
WO2023053059A1 (fr) * 2021-09-30 2023-04-06 Universidade Do Porto Composé antisalissure, procédé et utilisations de celui-ci
US11478464B1 (en) 2022-02-06 2022-10-25 King Faisal University Method for treating inflammation
US11786535B1 (en) 2023-02-22 2023-10-17 King Faisal University Methods of inhibiting cyclooxygenase

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059886A2 (fr) 1999-04-02 2000-10-12 Neurogen Corporation Derives aminoalkylimidazole fusionnes aryle et heteroaryle: modulateurs selectifs de recepteurs de bradykinine b¿2?
WO2003062392A2 (fr) 2002-01-18 2003-07-31 Ceretek Llc Procedes pour traiter des pathologies associees a un recepteur d'edg

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL280954A (fr) * 1961-07-14
US4088768A (en) * 1975-05-06 1978-05-09 Eli Lilly And Company N-heterocyclic ureas as immune regulants
DK40192D0 (da) * 1992-03-26 1992-03-26 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
ATE316076T1 (de) 1999-06-22 2006-02-15 Neurosearch As Benzimidazol-derivate und diese enthaltende pharmazeutische zusammensetzungen
US6316474B1 (en) * 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
EP1296945B1 (fr) * 2000-06-13 2004-08-04 Eli Lilly And Company Derives de sulfonamide
US20050113283A1 (en) * 2002-01-18 2005-05-26 David Solow-Cordero Methods of treating conditions associated with an EDG-4 receptor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000059886A2 (fr) 1999-04-02 2000-10-12 Neurogen Corporation Derives aminoalkylimidazole fusionnes aryle et heteroaryle: modulateurs selectifs de recepteurs de bradykinine b¿2?
WO2003062392A2 (fr) 2002-01-18 2003-07-31 Ceretek Llc Procedes pour traiter des pathologies associees a un recepteur d'edg

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NÄGELE, E.; SCHELHAAS, M.; KUDER, N.; WALDMANN, H., J. AM. CHEM. SOC., vol. 120, 1998, pages 6889

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007007069A1 (fr) * 2005-07-07 2007-01-18 Vernalis (R & D) Limited Composés azacycliques en tant qu’inhibteurs de canaux sodiques spécifiques aux neurones sensoriels
EP1904443A1 (fr) * 2005-07-12 2008-04-02 Bayer Cropscience Sa Nouveaux derives benzoheterocyclylethylbenzamide derivatives
JP2009504758A (ja) * 2005-08-15 2009-02-05 アイアールエム・リミテッド・ライアビリティ・カンパニー Ｔｐｏ模倣剤としての化合物および組成物
WO2007110221A1 (fr) * 2006-03-27 2007-10-04 Wex Pharmaceuticals Inc. Utilisation d'inhibiteurs des canaux sodiques pour traiter la douleur neuropathique consécutive à une chimiothérapie
US10624896B2 (en) 2006-03-27 2020-04-21 Wex Medical Limited Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
US11419873B2 (en) 2006-03-27 2022-08-23 Wex Medical Limited Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
US10149852B2 (en) 2006-03-27 2018-12-11 Wex Pharmaceuticals Inc. Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
US9018222B2 (en) 2006-03-27 2015-04-28 Wex Medical Limited Use of sodium channel blockers for the treatment of neuropathic pain developing as a consequence of chemotherapy
JP2009535414A (ja) * 2006-05-03 2009-10-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｖｒ１のベンゾイミダゾール系モジュレーター
US8431597B2 (en) 2007-06-29 2013-04-30 Pfizer Inc. Benzimidazole derivatives
WO2009049180A2 (fr) 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Amides d'hétéroaryle utilisés comme inhibiteurs de canaux sodiques sensibles à une différence de potentiel
EP2227453B1 (fr) * 2007-10-11 2016-03-09 Vertex Pharmaceuticals Incorporated Amides d'hétéroaryle utilisés comme inhibiteurs de canaux sodiques sensibles à une différence de potentiel
US11840497B2 (en) 2007-11-06 2023-12-12 Ptc Therapeutics, Inc. 4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
JP2019131618A (ja) * 2007-11-06 2019-08-08 バイオエレクトロン テクノロジー コーポレイション ミトコンドリア病を治療するための４−（ｐ−キノリル）−２−ヒドロキシブタンアミド誘導体
RU2518073C2 (ru) * 2008-12-26 2014-06-10 ДАЙНИППОН СУМИТОМО ФАРМА Ко., ЛТД. Новое бициклическое гетероциклическое соединение
US8946264B2 (en) 2009-03-05 2015-02-03 Daiichi Sankyo Company, Limited Pyridine derivative
US9688615B2 (en) 2011-03-03 2017-06-27 Degiacomo, Interim Trustee, Mark G. Benzimidazole inhibitors of the sodium channel
EP2681200A4 (fr) * 2011-03-03 2015-05-27 Zalicus Pharmaceuticals Ltd Inhibiteurs de type benzimidazole du canal sodique
KR20200019979A (ko) 2017-06-23 2020-02-25 쿄와 기린 가부시키가이샤 α, β 불포화 아미드 화합물
WO2018235926A1 (fr) 2017-06-23 2018-12-27 協和発酵キリン株式会社 COMPOSÉ AMIDE α, β-INSATURÉ
US11447471B2 (en) 2017-06-23 2022-09-20 Kyowa Kirin Co., Ltd. α,β-unsaturated amide compound
KR101938982B1 (ko) 2017-07-17 2019-01-15 연세대학교 산학협력단 자가포식 조절제를 포함하는 대사성 질환 치료용 약학 조성물
KR20190042940A (ko) * 2017-10-17 2019-04-25 성균관대학교산학협력단 Bietpc를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
KR102070882B1 (ko) 2017-10-17 2020-01-29 성균관대학교산학협력단 Bietpc를 유효성분으로 포함하는 암 예방 또는 치료용 약학적 조성물
EP3927330A4 (fr) * 2019-02-19 2022-11-30 The Regents of the University of California Modulateurs du récepteur nurr1
US11897871B1 (en) 2021-06-14 2024-02-13 Scorpion Therapeutics, Inc. Methods for treating cancer

Also Published As

Publication number Publication date
RU2006118312A (ru) 2007-12-10
WO2005042497A3 (fr) 2005-07-21
IL175252A0 (en) 2006-09-05
AU2004285053A1 (en) 2005-05-12
US7705031B2 (en) 2010-04-27
CA2543918A1 (fr) 2005-05-12
US20080306129A1 (en) 2008-12-11
NZ547109A (en) 2010-03-26
AU2004285053B2 (en) 2010-10-21
JP2007521325A (ja) 2007-08-02
KR20060115396A (ko) 2006-11-08
NO20062426L (no) 2006-05-29
US7309716B2 (en) 2007-12-18
EP1678145A2 (fr) 2006-07-12
CN1902181A (zh) 2007-01-24
ZA200603864B (en) 2007-09-26
US20050209282A1 (en) 2005-09-22

Similar Documents

Publication Publication Date Title
AU2004285053B2 (en) Benzimidazoles useful as modulators of ion channels
EP1891063B1 (fr) Derives bicycliques utilises en tant que modulateurs de canaux ioniques
US7605174B2 (en) Indane derivatives as modulators of ion channels
EP1888558B1 (fr) Derives bicycliques en tant que modulateurs de canaux ioniques
EP1934191B1 (fr) Derives de biphenyle utilises comme modulateurs des canaux ioniques sensibles au voltage
US20120308606A1 (en) Bicyclic derivatives as modulators of voltage gated ion channels
EP2043654A2 (fr) Thiénopyrimidines utiles en tant que modulateurs de canaux ioniques
EP2307412A2 (fr) Dérivés hétérocycliques en tant que modulateurs des canaux ioniques
EP1891039A1 (fr) Derives de quinoline utiles en tant que modulateurs de canaux ioniques
US7705002B2 (en) Biaryls useful as modulators of ion channels
EP1904491A2 (fr) Heterocycles utiles comme modulateurs de canaux ioniques
EP1877381A1 (fr) Pyridines utiles en tant que modulateurs de canaux ioniques
MXPA06004878A (en) Benzimidazoles useful as modulators of ion channels

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 10977609

Country of ref document: US

Ref document number: 200480039247.9

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 175252

Country of ref document: IL

Ref document number: 2543918

Country of ref document: CA

Ref document number: 2006538402

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004796881

Country of ref document: EP

Ref document number: PA/a/2006/004878

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2004285053

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 547109

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006/03864

Country of ref document: ZA

Ref document number: 200603864

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 1331/KOLNP/2006

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2004285053

Country of ref document: AU

Date of ref document: 20041028

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004285053

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020067010407

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2006118312

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2004796881

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020067010407

Country of ref document: KR